8-K: Nutriband Advances Fentanyl Patch with Positive FDA Feedback

Nutriband Inc. announced successful feedback from the U.S. FDA on its AVERSA FENTANYL abuse-deterrent patch, paving the way for an Investigational New Drug (IND) filing.

Summary

• Nutriband received final meeting minutes from its September 18, 2025, virtual meeting with the US FDA regarding its lead product, AVERSA FENTANYL (abuse deterrent fentanyl transdermal system).
• The meeting focused on Chemistry, Manufacturing, and Controls (CMC) plans for the product, from Investigational New Drug Application (IND) submission through 505(b)(2) New Drug Application (NDA) approval.
• The FDA confirmed the regulatory pathway for AVERSA FENTANYL is a 505(b)(2) NDA and provided guidance on the reference listed drug and bridging strategy.
• Feedback was provided on the registration batch plan, manufacturing process validation strategy, product specifications, and stability testing plans for clinical and commercial products.
• The FDA also discussed planned laboratory-based in vitro manipulation and extraction studies (Category 1) to characterize the product's abuse-deterrent properties.
• The Division acknowledged the importance of addressing fentanyl patch abuse, misuse, and accidental exposure, offering support and guidance for the development program.
• Nutriband is incorporating the FDA's feedback into its development program as it moves towards an IND filing to support a Human Abuse Potential (HAP) clinical study.
• AVERSA FENTANYL has the potential to be the first abuse-deterrent fentanyl patch approved worldwide, with estimated peak annual US sales of $80 million to $200 million.
• The AVERSA abuse-deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to successful engagement with the FDA, confirmation of a clear regulatory pathway, constructive feedback, and the potential for a first-in-class product addressing a significant unmet medical need. This represents a major de-risking event in the product's development cycle.

Positives

• Received positive and constructive feedback from the US FDA on Chemistry, Manufacturing, and Controls (CMC) plans for AVERSA FENTANYL.
• The FDA confirmed the regulatory pathway for AVERSA FENTANYL as a 505(b)(2) New Drug Application (NDA), providing clarity and a defined path forward.
• Guidance was provided on the relied-upon reference listed drug and bridging strategy, streamlining the development process.
• The FDA offered support and guidance for the development program, acknowledging the importance of addressing fentanyl patch abuse, misuse, and accidental exposure.
• AVERSA FENTANYL has the potential to be the first abuse-deterrent fentanyl patch approved globally, addressing a significant unmet medical need.
• The product has an estimated peak annual US sales potential of $80 million to $200 million, indicating strong market opportunity.
• Nutriband's AVERSA abuse-deterrent technology is protected by a broad international intellectual property portfolio with patents in 46 countries.

Risks

• Ability to develop the proposed abuse-deterrent fentanyl transdermal system and other proposed products.
• Ability to obtain patent protection for the abuse technology.
• Ability to obtain the necessary financing to develop products and conduct required clinical testing.
• Ability to obtain Federal Food and Drug Administration approval to market any product in the United States and other countries.
• Ability to market any product developed.
• Ability to create, sustain, manage, or forecast growth.
• Ability to attract and retain key personnel.
• Changes in business strategy or development plans.
• Competition and business disruptions.
• Adverse publicity and international, national, and local general economic and market conditions.
• Risks generally associated with an undercapitalized developing company.

Future Outlook

Nutriband plans to incorporate the FDA's feedback into its development program and move towards an Investigational New Drug (IND) filing to support a Human Abuse Potential (HAP) clinical study. The company aims to make AVERSA FENTANYL available in all major medical markets globally, with the potential to be the first abuse-deterrent fentanyl patch approved worldwide and achieve significant US sales.

Management Comments

• Alan Smith, Ph.D., Chief Operating Officer of Nutriband, Inc. and President of 4P Therapeutics, stated: "We are thankful for the opportunity to discuss the CMC aspects of our abuse deterrent fentanyl patch with the Agency. We are excited to incorporate the advice and constructive feedback that we received from the FDA into our development program as we move towards an IND filing in support of a Human Abuse Potential clinical study."

Industry Context

The announcement comes amidst a global opioid crisis and a critical need for safer pain management solutions that deter abuse, misuse, and accidental exposure. Fentanyl, while effective for severe pain, carries significant risks. Nutriband's AVERSA FENTANYL addresses this by aiming to be the first abuse-deterrent fentanyl patch, potentially setting a new standard in transdermal opioid delivery and risk mitigation.

Comparison to Industry Standards

• Currently, there are no abuse-deterrent fentanyl patches approved in the U.S. or any other country, positioning AVERSA FENTANYL as a potential first-in-class product.
• The FDA has previously issued warnings regarding the risks of fentanyl patch accidental exposure, particularly in children, highlighting the urgent unmet need that AVERSA FENTANYL aims to address.
• The partnership with Kindeva, a company with expertise in dermal drug delivery and an FDA-approved fentanyl patch, leverages established industry capabilities to develop this novel product.

Stakeholder Impact

• **Shareholders:** Positive regulatory progress and market potential could lead to increased investor confidence and potential share price appreciation.
• **Patients:** Potential for a safer fentanyl patch could provide a critical treatment option for opioid-tolerant patients requiring long-term pain management, reducing risks of abuse and accidental exposure.
• **Healthcare Providers:** A new abuse-deterrent option could offer a valuable tool in managing chronic pain while mitigating the risks associated with traditional fentanyl patches.
• **Regulatory Authorities:** The development of an abuse-deterrent fentanyl patch aligns with public health goals to combat the opioid crisis and improve drug safety.

Next Steps

• Incorporate FDA feedback into the development program.
• Proceed towards an Investigational New Drug (IND) filing.
• Initiate a Human Abuse Potential (HAP) clinical study for AVERSA FENTANYL.

Key Dates

Recommendation

The positive feedback from the FDA, including confirmation of the 505(b)(2) regulatory pathway and constructive guidance on CMC plans, significantly de-risks the development of AVERSA FENTANYL. This product has the potential to be the first abuse-deterrent fentanyl patch globally, addressing a critical unmet medical need with substantial market potential ($80M-$200M peak annual US sales). This regulatory clarity and progress, coupled with strong intellectual property, positions Nutriband for significant future growth and makes it an attractive investment at this stage of development.

Keywords

Fentanyl Patch, Abuse Deterrent, FDA, AVERSA FENTANYL, Transdermal System, Opioid Abuse, Drug Development, Pharmaceutical, IND Filing, NDA Pathway, Kindeva